Who Is the Highest Paid Doctor Specialty—and Where Do Regenerative Doctors Rank?

Money always creeps into medical conversations. Patients ask about costs. Medical students weigh lifestyle against loans. And lately, a new question shows up more often in my clinic: where do those “regenerative medicine doctors” fit into the picture, and are they the new high earners?

To answer that honestly, you have to understand both traditional medical specialties and the business reality of cash-pay regenerative treatments. The picture is more nuanced than glossy clinic ads or salary charts on social media suggest.

This is a walk through what different doctors earn, what regenerative medicine really is, what it costs, and how to think clearly about success rates and risks.

Who is the highest paid doctor specialty?

In the United States, the highest paid doctor specialties cluster around procedures that are technically complex, high demand, and often reimbursed well by insurance. Exact rankings shift slightly each year depending on the survey, but the same fields sit near the top.

Across recent national compensation reports, the top earners most often include:

• Orthopedic surgery: roughly \$600,000 to \$800,000+ per year in many practices
• Plastic surgery: often \$550,000 to \$750,000+
• Cardiology (especially interventional): commonly \$550,000 to \$700,000
• Gastroenterology: frequently \$500,000 to \$650,000
• Radiology (especially interventional or high-volume diagnostic): often \$500,000 to \$650,000

Those numbers are ballparks, not guarantees. A surgeon in a large urban academic center with heavy research may earn much less than a community-based proceduralist in a high-volume practice. Call burden, partnership status, ownership in surgery centers, and productivity bonuses reshape the final picture.

On the flip side, when people ask “What is the lowest paying doctor specialty?”, the answer is fairly consistent. Primary care and some cognitive specialties tend to sit at the bottom of income tables. Family medicine, pediatrics, psychiatry, infectious disease, and public health often earn in the \$225,000 to \$280,000 range in the US, sometimes less early in a career or in lower-paying markets. Again, context matters: a pediatrician who owns multiple clinics can out-earn a salaried specialist without any business stake.

The point is not to glorify one group and dismiss another. It is to show the spread: roughly a 2 to 3-fold difference in average pay between the highest and lowest paying doctor specialties, before you layer on business ownership.

Where do regenerative medicine doctors rank in pay?

“Regenerative medicine doctor” is not a board-certified specialty in the same way as cardiology or neurosurgery. It is a clinical focus that crosses several fields. If you walk into five “regenerative” clinics, you might meet:

• A sports medicine or physical medicine & rehabilitation (PM&R) physician doing platelet-rich plasma (PRP) and joint injections
• An orthopedic surgeon who uses biologics alongside surgery
• An interventional pain physician offering spine and joint procedures with biologic products
• A family medicine or emergency medicine physician who has pivoted into a cash-pay musculoskeletal practice
• In some cases, providers without residency training or board certification at all

That variety is why you will not find regenerative medicine listed as its own income category in major physician compensation surveys.

So how much do regenerative medicine doctors make? In the US, someone with a strong musculoskeletal background, a steady referral stream, and a mostly cash-pay orthobiologics practice might earn Regenerative Medicine Doctor Scottsdale from the mid \$300,000s to \$700,000+ annually. There are outliers who make more, largely due to business structure, not clinical work alone: owning the clinic, selling courses, or running large marketing funnels.

On the other end, a physician adding a few PRP injections to a general practice may see only a modest bump in income. Overhead for biologic procedures, malpractice coverage, staff, and marketing chew into revenue quickly.

Where they “rank” relative to other specialties depends on:

• Their original specialty (sports medicine vs dermatology vs PM&R)
• How much of their practice is cash-pay vs insurance
• Whether they own their facility and ancillary services
• Their comfort with sales and marketing

A well-run regenerative musculoskeletal practice can certainly reach high surgical or interventional income levels. But that is business, not magic. There is no built-in salary tier called “regenerative doctor” that automatically drops you into the top bracket.

What is a regenerative medicine doctor, really?

Patients often ask, “What is a regenerative medicine doctor, exactly? Are they stem cell doctors?”

Clinically, regenerative medicine aims to help the body repair or replace damaged tissues by using cells, growth factors, scaffolds, or gene-based techniques. In orthopedics and sports medicine, that usually means biologic injections to reduce pain and improve function in arthritis, tendon injuries, or ligament problems.

In practice, the clinicians I would personally trust in this space usually have:

• Formal training in a musculoskeletal or interventional field, such as PM&R, sports medicine, orthopedics, or interventional pain, with daily experience evaluating joints, tendons, and spine.
• Ultrasound or fluoroscopy (x-ray) skills to place injections accurately.
• A willingness to say “no” to procedures when the evidence is weak or the odds of benefit are low.

There are also regenerative medicine researchers, often MDs or PhDs, who work in labs on stem cells, tissue engineering, or gene therapies. Their work may never involve private-pay procedures, but they are every bit as “regenerative” as anyone operating a clinic.

If you are a patient, the more helpful question is not “Are you a regenerative doctor?” but “What is your core specialty, how many of these procedures do you perform, and what outcomes do you track?”

The four types of regeneration: lab vs clinic

Students sometimes ask, “What are the 4 types of regeneration?” They usually mean a concept from developmental biology. In that basic science context, regeneration gets categorized as epimorphosis, morphallaxis, compensatory regeneration, and so on, describing how organisms like salamanders regrow limbs.

In clinical Regenerative Medicine Doctor Scottsdale regenerative medicine, we rarely use that language. Instead, doctors often think in terms of therapeutic categories. For a patient, it makes more sense to look at four broad types of interventions you might encounter in musculoskeletal or orthopedic regenerative care:

1. Autologous cell-based therapies: These use your own cells, such as bone marrow aspirate concentrate or minimally manipulated fat-derived cell preparations, injected into joints, tendons, or spine structures.
2. Blood-derived products: Platelet-rich plasma (PRP), platelet lysate, and other derivatives of your own blood that concentrate growth factors to stimulate healing in tissues.
3. Allogeneic biologics: Products sourced from donated birth tissues (such as amniotic or umbilical-derived materials) or other donors, processed into injectable products. Many of these are heavily marketed but sit in a regulatory gray zone and often do not contain living stem cells by the time they reach the syringe.
4. Tissue engineering and scaffolds: Materials designed to support tissue regrowth or integration, such as certain cartilage scaffolds or biologic patches used in surgery.

On the frontier, there are also gene therapies and advanced cell manipulations, but those are largely confined to clinical trials or highly regulated research programs.

Understanding which category a proposed treatment falls into helps you ask the next critical questions: what is the evidence, how is it regulated, and who is actually a good candidate?

What is the average cost of regenerative medicine?

When someone asks, “What is the average cost of regenerative medicine?”, they are usually thinking about joint injections, back procedures, or soft tissue treatments. There is no single average, but there are recognizable ranges in the US:

PRP injections:

For a single PRP injection to a joint or tendon, fees often run from \$500 to \$2,500 depending on geography, the quality of the centrifuge system, whether imaging guidance is used, and whether multiple body areas are treated. Packages of several injections can rise higher.

Bone marrow or “stem cell” procedures:

Harvesting bone marrow or fat, processing it, and reinjecting it into one or more joints or spinal structures is more involved. Costs often range from \$4,000 to \$10,000 per region, sometimes more if multiple joints or the spine are treated at once. Marketing-heavy clinics that bundle in “full-body” approaches or travel services can reach \$15,000 to \$20,000.

Birth tissue or donor-derived products:

Fees for amniotic or umbilical-derived injections vary widely. A single injection can range from around \$1,500 to more than \$5,000 depending on the product and clinic markup.

Tissue-engineering or surgical biologics:

When regenerative products are used inside an operating room, the charges get rolled into surgical and facility bills, which can make it hard for patients to see a clean line item.

Those amounts are usually paid out-of-pocket. That is what makes the next question so critical.

Will insurance pay for regenerative medicine?

Most of the time, no.

That is the blunt answer for patients wondering, “Will insurance pay for regenerative medicine?” or more specifically “Does insurance cover Kinetix or other named biologic brands?”

Current insurance policies in the US tend to view many regenerative procedures as experimental or investigational, especially:

• PRP for most orthopedic indications
• Bone marrow or adipose-derived “stem cell” injections for joints or spine
• Most amniotic or umbilical-derived injectable products promoted as regenerative

There are a few exceptions. For example, some plans have begun to cover PRP for specific conditions like chronic tennis elbow, and certain FDA-approved biologics used in very particular surgical or wound-care contexts are covered.

Regarding specific branded products, such as Kinetix or similar orthobiologic or regenerative injections, coverage is inconsistent and heavily dependent on the insurer, diagnosis, and how the product is billed. Many commercial plans classify these therapies as non-covered or investigational. When there is any chance of coverage, strict pre-authorization is usually required, and even then denials are common.

If a clinic tells you “We can bill this to insurance,” ask very direct questions:

• Is it pre-authorized in writing for this specific product and diagnosis?
• What does the insurer list as the member out-of-pocket expectation?
• What happens if the claim is denied after the procedure?

If you are not comfortable with the answers, assume you may be paying most or all of the bill yourself.

What is the biggest problem with regenerative medicine?

Technologically, regenerative medicine is one of the most exciting areas in healthcare. Clinically, the biggest problem right now is the gap between marketing and evidence.

Three issues show up again and again when I review real-world cases:

First, inflated or misleading claims. Many clinics advertise “stem cell” procedures that in reality use products with no living stem cells by the time they are injected. Patients pay premium prices for therapies that do not match the promise on the brochure.

Second, uneven expertise. Some clinicians have deep musculoskeletal training, perform image-guided injections daily, and participate in registries or research. Others attend a weekend course, buy an expensive centrifuge, and begin offering injections with minimal understanding of biomechanics, rehab, or realistic outcome expectations.

Third, regulatory gray zones. The FDA has clear rules about what counts as more-than-minimally manipulated human cells or tissues and what requires formal approval as a drug or biologic. Yet many products are sold under loopholes or claimed exemptions that will likely not stand long term. When enforcement catches up, some therapies vanish overnight, leaving patients with no recourse.

If you strip away the hype and look at solid data, regenerative medicine absolutely has legitimate uses. PRP in certain tendon and knee arthritis cases, for example, has growing support. But it is not a miracle cure, and it does not erase the need for proper diagnosis, rehab, and realistic goal-setting.

What are the disadvantages of regenerative medicine?

Every intervention carries trade-offs. With regenerative approaches, several disadvantages deserve special attention:

Cost burden. Most regenerative procedures are not covered by insurance, and patients often finance treatments or dip into savings. When the outcome is good, they see it as worth it. When the result is mediocre, the financial sting is real.

Variable response. Even in conditions with decent evidence, such as mild to moderate knee osteoarthritis treated with PRP, a significant minority of patients do not experience meaningful improvement. You pay hundreds or thousands of dollars for an attempt, not a guarantee.

Limited regulation of marketing claims. Because many procedures are performed in-office and markets move faster than regulators, patients are often relying on clinic promises, testimonials, and social media, rather than large, definitive trials.

Timing risk. Some patients pursue regenerative procedures too late, when joint destruction is advanced and the odds of benefit have already dropped. Others chase biologic injections for problems that would respond better to focused physical therapy or surgical repair.

Procedure discomfort and downtime. Which leads naturally to the next common question.

Is regenerative medicine painful?

The answer depends heavily on what you are having done.

Simple PRP injections into a superficial tendon or single joint, done with local anesthetic and ultrasound guidance, are usually moderately uncomfortable. Most patients describe a stinging or pressure sensation and post-procedure soreness for a few days, similar to a flare-up of their usual pain.

Bone marrow aspiration from the pelvis is more involved. Even with local anesthetic and sometimes mild sedation, patients often feel drilling pressure and deep ache during and after the harvest. The injection of the concentrated cells into a joint or spine structure can also be painful, though this is often improved with local anesthetic and careful technique.

Spine procedures require particular care. Injections around discs, facet joints, or sacroiliac joints can cause transient sharp pain or pressure. With image guidance and proper preparation, they are usually tolerable, but they are not “spa” treatments.

The phrase “minimally invasive” does not mean painless. It means no large incisions and shorter recovery than surgery. A candid doctor will tell you exactly what to expect, how long soreness usually lasts, and what pain control options exist after your procedure.

What is the success rate of regenerative medicine?

Patients understandably want a number: “What is the success rate of regenerative medicine?” The problem is that the phrase covers an enormous range of conditions and procedures.

Take one example with relatively good data: PRP for knee osteoarthritis. Across multiple randomized studies and meta-analyses, many show that PRP can reduce pain and improve function in mild to moderate knee arthritis, often outperforming hyaluronic acid injections and sometimes lasting 6 to 12 months or more. Roughly 60 to 80 percent of appropriately selected patients report meaningful improvement.

But that statistic does not apply to:

• Severe bone-on-bone arthritis with major deformity
• Complex multi-ligament knee instability
• Advanced autoimmune joint disease

For those, the “success rate” of PRP in returning you to heavy labor or sport is far lower.

Stem cell procedures for arthritis, using bone marrow or fat-derived cells, have more mixed evidence. Some studies show improvement, others show results similar to placebo or steroid injections. Success rates vary widely because protocols, cell preparations, and patient selection are all over the map.

The most honest way to think about success is in layers:

• First, define success: less pain, more function, delay of surgery, or structural healing on imaging.
• Second, ask your doctor what percentage of their own patients with your exact diagnosis and severity achieve that goal, not vague “80 percent improvement” claims pooled across everything they treat.
• Third, weigh that probability against cost, downtime, and alternative options like surgery, physical therapy, or activity modification.

If your clinician cannot answer those questions in plain language, or becomes evasive, you have learned something about your odds.

Who is a good candidate for regenerative medicine?

When I walk through options with patients, I am less interested in who is excited and more interested in who is likely to benefit. As a quick mental framework, people in the following situation often make the most sense to consider biologic or regenerative injections:

• Clear diagnosis of a musculoskeletal problem that has failed standard conservative care (exercise therapy, load management, basic medications)
• Imaging that shows tissue damage that is meaningful but not end-stage destruction
• Functional goals that are realistic: reducing pain to improve daily function or sport participation, not necessarily making a severely arthritic joint “young” again
• Willingness to engage fully in rehabilitation and movement retraining after the procedure
• Financial ability to tolerate the cost if it does not produce the desired outcome

Age alone does not determine candidacy. I have seen patients in their 60s respond beautifully to PRP for tennis elbow and others in their 30s with poor outcomes because the underlying biomechanics never changed.

On the other hand, someone with advanced bone-on-bone hip arthritis who cannot walk a block is often better served by a joint replacement than by repeated expensive injections that can only nudge around the edges of a very large problem.

Where did Joe Rogan get his stem cell treatment?

Public figures often influence how patients think about regenerative medicine. Joe Rogan is one of the most cited examples in my clinic conversations.

He has spoken on his podcast about receiving stem cell treatments at a clinic in Panama, commonly understood to be the Stem Cell Institute in Panama City, run by Dr. Neil Riordan. The treatments described involved intravenous infusions and injections for joint issues, delivered outside the United States regulatory framework.

That detail matters. Many of the intravenous stem cell infusions promoted for “whole body” benefits or general rejuvenation are not approved by the FDA in the U.S. Patients travel to countries like Panama, Mexico, or elsewhere to access these services, which are often marketed to international clients.

Joe Rogan’s personal report of benefit is anecdotal. It is not the same as a randomized controlled trial. It also reflects access to resources and risk tolerance that do not automatically map onto what is wise for every patient.

When a patient says, “Where did Joe Rogan get his stem cell treatment, and should I go there?” my answer typically separates three things:

1. Where he went (a particular private clinic in Panama).
2. What was actually done (intravenous and local injections of cells in a less regulated environment).
3. Whether similar or alternative options with better safety data or regulation exist closer to home for that patient’s specific condition.

The shine of celebrity stories should never replace sober risk–benefit thinking for your own situation.

What country is best for stem cell treatment?

There is no single “best” country for stem cell treatment. Each region has its own strengths and trade-offs.

If your priority is regulatory oversight and evidence-based care, the United States, Canada, and many countries in Western Europe maintain fairly strict control over which stem cell therapies are allowed outside research settings. That can be frustrating if you are looking for experimental options, but it protects patients from some of the more speculative or unsafe practices.

If your priority is access to aggressive experimental therapies, you will see a lot of marketing from clinics in places like Mexico, Panama, and some parts of Asia or Eastern Europe. Regulatory environments may be looser, and clinics can offer intravenous or high-dose stem cell infusions not permitted at home. That freedom comes with real risks: less standardized product quality, limited recourse if complications occur, and weaker data behind the interventions.

When patients ask me, “What country is best for stem cell treatment?”, I encourage them to ask a different question: “Where can I receive the safest, best-studied treatment for my specific condition, from clinicians who are accountable to my home standards of care?” For many, that ends up being a reputable center in their own country, sometimes as part of a clinical trial.

Travel abroad for experimental therapy may still be reasonable in select cases, but it should never be a spur-of-the-moment decision based on a single testimonial video.

Does fasting for 72 hours regenerate cells?

The idea that a 72-hour fast can “regenerate” your cells circulates widely online. There is some science behind parts of this, but the story is more nuanced than the headlines suggest.

Research on prolonged fasting, particularly by groups like Valter Longo’s, has shown in mice that cycles of extended fasting can reduce certain immune cell counts and, during refeeding, stimulate hematopoietic stem cells in the bone marrow to repopulate them. Some early human studies suggest that multi-day fasts or fasting-mimicking diets can shift immune cell profiles and metabolic markers.

That is interesting biology, but it does not mean a 72-hour water fast will regrow joint cartilage, repair torn tendons, or regenerate organs. In practice:

• Most of the “regeneration” discussed in these studies relates to turnover and renewal of specific blood and immune cells, not wholesale tissue rebuilding.
• Human data are limited, and fasting for 72 hours is not risk-free, especially for people with diabetes, cardiovascular disease, eating disorders, or those on certain medications.
• Fasting is not a substitute for targeted regenerative therapies in injured joints, spine, or organs.

If you are otherwise healthy and curious about fasting, talk with a physician who understands your medical history. Do not combine aggressive fasting with high-risk travel, heavy exercise, or major procedures without guidance. And do not assume that a three-day fast is a magic reset button for all tissues.

Where does this leave patients and physicians?

Regenerative medicine sits at an intersection: genuine promise from cell biology and tissue engineering, real-world stories of benefit, and equally real stories of oversold procedures and drained savings.

Orthopedic surgeons, cardiologists, gastroenterologists, and other proceduralists still lead the traditional income rankings. Regenerative doctors, where they exist as a focused practice, can sit anywhere on that spectrum, largely depending on their underlying specialty and business structure.

For patients, three anchors help keep the decision-making grounded:

Evidence before excitement. Ask directly about randomized trials, registries, and outcomes data specific to your diagnosis and severity, not across “thousands of patients with all kinds of conditions.”

Clarity about cost and coverage. Treat promises of “We can probably get insurance to pay” with caution unless you see documentation. Expect that many regenerative procedures will be out-of-pocket and weigh that against other options.

Fit between treatment and goals. A well-timed PRP injection can help an athlete return to play or delay a knee replacement. The same injection in a severely deformed joint may only lighten your wallet.

Regenerative medicine is neither a scam nor a miracle. It is a tool set. In the hands of thoughtful clinicians, used for the right people at the right moment, it can be extremely valuable. The challenge for both patients and doctors is to keep the conversation honest, specific, and grounded in more than marketing language.

Integrated Spine, Pain and Wellness
7425 E Shea Blvd Suite 102, Scottsdale, AZ 85260
4806608823